Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
acrogranin CRISPR Activation Plasmid (h): sc-401924-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- acrogranin CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- acrogranin CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by acrogranin CRISPR Activation Plasmid (h) and acrogranin CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GRN transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: acrogranin Antibody (C-11): sc-377036
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
acrogranin CRISPR Activation Plasmid (h) | sc-401924-ACT | 20 µg | $397.00 |
GRN encodes acrogranin (progranulin), a secreted glycoprotein that supports cell growth, survival, and tissue remodeling through modulation of inflammatory signaling and protease activity in the extracellular milieu. Acrogranin influences lysosomal homeostasis and endosomal trafficking, and its cleavage into granulins can reshape cytokine responses and cellular stress programs. In the nervous system it contributes to microglial function, synaptic maintenance, and neuronal resilience, while in peripheral tissues it affects wound repair and stromal–epithelial interactions. Dysregulated GRN expression or haploinsufficiency is linked to neurodegeneration and immune dysfunction, and altered progranulin signaling is also studied in cancer and fibrotic biology as a regulator of proliferation and inflammation.
acrogranin CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GRN expression without altering the underlying DNA sequence.
acrogranin CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GRN locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GRN transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous acrogranin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GRN locus and enabling the study of acrogranin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of acrogranin pathway restoration in tumor cells with silenced or reduced GRN expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.